Evaluation of the accuracy of the Asanté assay as a point-of-care rapid test for HIV-1 recent infections using serum bank specimens from blood donors in South Africa, July 2018 - August 2021
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i10.678Keywords:
AsantéTM HIV-1 Rapid Recency® Assay, Established infection, ELISA, HIV Rapid Assay, the Maxim HIV-1 Limiting Antigen (LAg) Avidity Assay, Point of Care, Sensitivity, Specificity, South AfricaAbstract
Background. Point-of-care (POC) rapid recency testing can be used as a cost-effective tool to identify recently infected individuals (i.e. infected within the last 12 months) in near-real time, support epidemic control and identify hotspots for transmission as part of recent infection surveillance.
Objective. To evaluate the performance of the Asanté (HIV-1) rapid recency assay as a POC rapid test among blood donors in South Africa (SA). Methods. The study was a cross-sectional and validity study of the Asanté HIV-1 Rapid Recency Assay performed on 715 consecutively archived plasma donor specimens from the SA National Blood Services to determine their recency and established HIV infection status. ELISA and rapid assays for HIV antibody detection were used as the reference-testing standard for confirming an infection, while the Maxim HIV-1 limiting antigen (LAg) avidity assay was used as a reference for comparing HIV recency status. Validity tests (sensitivity, specificity, negative and positive predictive values) and Cohen-Kappa tests of the agreement were conducted to compare the Asanté HIV-1 rapid recency assay results with the reference tests.
Results. Of the 715 studied blood samples, 63.1% (n=451/715) were confirmed to be HIV-positive based on the reference standard. The sensitivity and specificity of the Asanté HIV-1 rapid recency assay in diagnosing established HIV infection compared to the ELISA were 98.4% (95% CI 96.7 - 99.3) and 99.6% (95% CI 97.6 - 100), respectively. Compared with HIV rapid assay, the sensitivity and specificity of the Asanté HIV-1 rapid recency assay was 98.7% (95% CI 97.0 - 99.4) and 99.2% (95% CI 97.1 - 100), respectively. Of the 451 HIV-positive blood samples, 43% were confirmed as recent HIV infections by the Maxim HIV-1 LAg avidity assay. There was high agreement between the Asanté HIV-1 rapid recency assay and the Maxim HIV-1 LAg avidity assay (94.1%, k=0.879, p<0.0001). The sensitivity and specificity of the Asante HIV-1 assay was 89.4% (95% CI 84.0 - 93.0) and 97.7% (95% CI 94.8 - 99.0), respectively.
Conclusion. The Asanté HIV-1 rapid recency assay test results demonstrated high accuracy (>90%) compared with the HIV ELISA and rapid assays for determining established infection and the Maxim HIV-1 LAg avidity assay for classifying recent HIV-1 infections. The assay’s sensitivity for established infections was below the World Health Organization criteria (<99%) for POC devices. The Asanté HIV-1 rapid recency assay can be used to distinguish between recent and long-term infections, but may not be considered a POC test for determining HIV infection.
References
JointUnitedNationsProgrammeonHIVandAIDS.CountryFactSheetsSouthAfrica2021.https:// www.unaids.org/en/regionscountries/countries/southafrica (accessed 5 August 2022).
Joint United Nations Programme on HIV and AIDS. Fact Sheet 2022 https://www.unaids.org/sites/ default/files/media_asset/UNAIDS_FactSheet_en.pdf (accessed 5 August 2022).
Joint United Nations Programme on HIV and AIDS. 90-90-90 An ambitious treatment target to help end the AIDS Epidemic. Geneva, 2014 UNAIDS/JC2684. https://www.unaids.org/en/resources/ documents/2017/90-90-90 (accessed 11 February 2022).
Joint United Nations Programme on HIV and AIDS. Understanding Fast-Track. Geneva, Switzerland. 2015. https://www.unaids.org/en/resources/documents/2015/201506_JC2743_ Understanding_FastTrack (accessed 13 September 2021).
Johnson CC, Dalal S, Baggaley R, Taegtmeyer M. A public health approach to addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes. J Int AIDS Society 2017;20(Suppl 6):S22190. https://doi.org/10.7448/IAS.20.7.22190
National Department of Health. National HIV Testing Services: Policy 2016, Republic of South Africa. Pretoria, South Africa: National Department of Health, 2016. https://sahivsoc.org/Files/ HTS%20Policy%2028%20July%20final%20copy.pdf (accessed 6 March 2022).
SimbayiLC,ZumaK,ZunguN,etal.SouthAfricanNationalHIVPrevalence,Incidence,Behaviour and Communication Survey, 2017. Cape Town, HSRC Press, 2019. http://www.hsrc.ac.za/uploads/ pageContent/10779/SABSSM%20V.pdf (accessed 7 March 2022).
Mabunda SA, Sigovana K, Chitha W, Apalata T, Nomatshila S. Socio-demographic associations of HIV among women attending antenatal care in selected rural primary care facilities in South Africa’s Eastern Cape province. BMC Infect Dis 2021;21(1):61. https://doi.org/10.1186/s12879-020-05744-7
Incidence Assay Critical Path Working Group. More and better information to tackle HIV epidemics: Towards improved HIV incidence assays. PLoS Med 2011;8(6):e1001045. https://doi. org/10.1371/annotation/0931760c-95fa-441c-a797-7b410a4c9326
MastroTD,KimAA,HallettT,etal.EstimatingHIVIncidenceinpopulationsusingtestsforrecent infection: Issues, challenges and the way forward. J HIV AIDS Surveil Epidem 2010;2(1):1-14.
Kim AA, Behel S, Northbrook S, Parekh BS. Tracking with recency assays to control the epidemic:
Real-time HIV surveillance and public health response. Aids 2019;33(9):1527-1529. https://doi.
org/10.1097/QAD.0000000000002239
World Health Organization, AIDS JUNPoHa. WHO Protocol for Performance Laboratory Evaluation of HIV Serology Assays. Geneva: WHO, 2017. https://www.who.int/diagnostics_laboratory/ evaluations/alter/171219_protocol_pqdx_030_v10_hiv_serology.pdf (accessed 15 March 2022).
WorldHealthOrganization.EstimatingHIVincidenceusingHIVcasesurveillance.Geneva:WHO, 2015. https://www.who.int/publications/i/item/WHO-HIV-2017.03 (accessed 6 March 2022).
World Health Organization. When and how to use assays for recent infection to estimate HIV incidence at a population level. Geneva: WHO, 2011. https://www.who.int/diagnostics_laboratory/ hiv_incidence_may13_final.pdf (accessed 6 March 2022).
Bärnighausen T, Wallrauch C, Welte A, et al. HIV incidence in rural South Africa: Comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PloS One 2008;3(11):e3640. https://doi.org/10.1371/journal.pone.0003640
Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: Potential for HIV-1 incidence estimates and avidity maturation studies. PloS One 2012;7(3):e33328. https://doi.org/10.1371/journal.pone.0033328
Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010;26(1):61-71. http://doi.org/10.1089/aid.2009.0133
Centers for Disease Control and Prevention. Terms, definitions, and calculations used in CDC HIV surveillance publications. Atlanta: CDC, 2016. https://www.cdc.gov/hiv/statistics/surveillance/ terms.html (accessed 7 February 2022).
YufenyuyEL,DetorioM,DobbsT,etal.PerformanceevaluationoftheAsanteRapidRecencyAssay for verification of HIV diagnosis and detection of recent HIV-1 infections: Implications for epidemic control. PLOS Glob Pub Health 2022;2(5):e0000316. https://doi.org/10.1371/journal.pgph.0000316
Parekh B, Detorio M, Shanmugam V, et al. Performance evaluation of Asante Rapid Recency Assay for HIV diagnosis and detection of recent infection: Potential for surveillance and prevention. Paris: Centers for Disease Control, 2017.
Granade TC, Nguyen S, Kuehl DS, Parekh BS. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses 2013;29(1):61-67. http://doi.org/10.1089/aid.2009.0133
YufenyuyEL,DetorioM,TanX,etal.EvaluationofrapidtestsforrecentHIVInfection:Implications for real-time surveillance and epidemic control. Atlanta: Centers for Disease Control, 2019. https:// hivtestingconference.org/wp-content/uploads/2019/04/42-Parekh.pdf (accessed 8 March 2022).
CohenJF,KorevaarDA,AltmanDG,etal.STARD2015guidelinesforreportingdiagnosticaccuracy studies: Explanation and elaboration. BMJ Open 2016;6(11):e012799. https://doi.org/10.1136/ bmjopen-2016-012799
Castro AR, Kikkert SE, Fears MB, Pope V. Defibrination of blood plasma for use in serological tests for syphilis. Clin Diagnostic Lab Immunol 2002;9(6):1376-1378. https://doi.org/10.1128/ cdli.9.6.1376-1378.2002
World Health Organization. WHO manual for organising a national external quality assessment programme for health laboratories and other testing sites Geneva: WHO, 2016. https://apps.who. int/iris/handle/10665/250117 (accessed 6 March 2022).
World Health Organization. HIV assays: Operational characteristics (phase 1), report 15, antigen/ antibody ELISAs. Geneva: WHO, 2004. https://www.who.int/diagnostics_laboratory/publications/ en/HIV_Report15.pdf (accessed 26 February 2022).
Parekh BS, Ou CY, Fonjungo PN, et al. Diagnosis of human immunodeficiency virus infection. Clin Microbiol Rev 2019;32(1):e00064-18. https://doi.org/10.1128/CMR.00064-18
McHugh ML. Interrater reliability: The kappa statistic. Biochemia Medica 2012;22(3):276-282.
Pereira P. Basic validation of qualitative tests. Madison: Westgard QC. 2016. https://www.westgard.
com/basic-method-validation.htm (accessed 13 September 2021).
DuongYT,KassanjeeR,WelteA,etal.RecalibrationofthelimitingantigenavidityEIAtodetermine
mean duration of recent infection in divergent HIV-1 subtypes. PLoS One 2015;10(2):e0114947.
https://doi.org/10.1371/journal.pone.0114947
World Health Organization. HIV assays operational characteristics: HIV rapid diagnostic tests (detection of hiv 1/2 antibodies) report 17. Geneva: WHO, 2013. https://apps.who.int/iris/ handle/10665/93679 (accessed 6 March 2022).
Mehra B, Bhattar S, Bhalla P, Rawat D. Rapid tests versus ELISA for screening of HIV infection: Our experience from a voluntary counselling and testing facility of a tertiary care centre in North India. ISRN AIDS 2014;729684. https://doi.org/10.1155/2014/296840
Augusto ÂDR, Iriemenam NC, Kohatsu L, et al. High level of HIV false positives using EIA-based algorithm in survey: Importance of confirmatory testing. PLoS One 2020;15(10):e0239782. https:// doi.org/10.1371/journal.pone.0239782
Galiwango RM, Ssuuna C, Kaleebu P, et al. Validation of the Asante HIV-1 Rapid recency assay for detection of recent HIV-1 infections in Uganda. AIDS Res Hum Retroviruses 2021;37(12):893-896. https://doi.org/10.1089/AID.2020.0279
Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular epidemiology of HIV-1 in African countries: A comprehensive overview. Pathogens 2020;9(12):1072. https://doi.org/10.3390/ pathogens9121072
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Beverley Singh, Prof, Ms, Dr, Mr, Ms, Mr, Mrs
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
